5442932025-04-012025-06-305442932025-04-012025-06-30in-capmkt:OtherExpenses1Member5442932025-04-012025-06-30in-capmkt:OtherExpenses2Member5442932025-04-012025-06-30in-capmkt:OtherExpenses3Member5442932025-04-012025-06-30in-capmkt:OtherExpenses4Member5442932025-04-012025-06-30in-capmkt:OtherExpenses5Member5442932025-04-012025-06-30in-capmkt:OtherExpenses6Member5442932025-04-012025-06-30in-capmkt:OtherExpenses7Member5442932025-04-012025-06-30in-capmkt:OtherExpenses8Member5442932025-04-012025-06-30in-capmkt:OtherExpenses9Member5442932025-04-012025-06-30in-capmkt:OtherExpenses10Member5442932025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15442932025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25442932025-04-012025-06-30AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares544293SURAKSHANOTLISTEDINE877V01027SURAKSHA DIAGNOSTIC LIMITEDMain BoardEquity2025-04-012026-03-312025-08-082025-07-29INRLakhsQuarterlyFirst quarterSingle segmentDIAGNOSTIC2025-08-0817:40:002025-08-0818:26:00Declaration of unmodified opinionfalsefalseNo default2025-04-012025-06-30UnauditedStandalone7027900001095700071374700086880000001241480002658500091537000253389000582539000131208000013120800028567000415400032721000098487000000098487000194600010043300010416200021.891.89001.891.890001.The standalone financial results for the quarter ended 30 June 2025 of Suraksha Diagnostic Limited have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard Ind AS notified under Section 133 of the Companies Act 2013 as amended read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended the regulations. <BR> 2. These financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 08 August 2025. The statutory auditor have carried out limited review on these financial results and have issued an unmodified conclusion. <BR> 3. The standalone figures for the quarter ended 31 March 2025 are the balancing figures between the audited standalone figures in respect of the full financial year and the published unaudited year to date standalone figures up to the third quarter of the financial year. <BR> 4. The figures for the quarter ended June 30 2024 have been extracted from the audited special purpose Ind AS Interim standalone financial statements of the Company prepared for the purpose of inclusion in the offer documents. <BR> 5. The Company is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 Operating Segments. <BR> 6. During the quarter ended 31 March 2025 the Company had entered into a Share Subscription Agreement for subscribing to 95841 equity shares of Rs.10 each representing 16.17 percent of the total equity share capital of Fetomat Wellness Private Limited. Subsequent to financial year ended 31 March 2025 the Company had entered into Share Purchase Agreements with existing shareholders of Fetomat for acquisition of 277582 equity shares of Rs. 10 each representing 46.83 percent of the total equity share capital of Fetomat resulting in Fetomat becoming a subsidiary of the Company. <BR> 7. These financial results are also available on the Companys website at www.surakshanet.com and on the stock exchange websites www.bseindia.com and www.nseinda.com. <BR> 8. Previous periods years figures have been regrouped reclassified wherever necessary to conform to current periods years classification.Impairment Loss-8904000Advertisement6339000Rent Expenses13904000Power and fuel23750000Professional fees paid117736000Repairs and maintenance20834000Information technology expenses13365000Security and housekeeping charges16502000Commission to collection centre11616000Other Expenses38247000Remeasurement gain/(loss) of net defined benefit plan2600000Income tax effect on above-6540001946000001946000UnauditedtrueMSKA & Associatestrue2027-07-31